Neural Regeneration Research ›› 2024, Vol. 19 ›› Issue (7): 1427-1428.doi: 10.4103/1673-5374.387987

Previous Articles     Next Articles

Hydroxytyrosol and Parkinson’s disease: protective actions against alpha-synuclein toxicity

Ruth Hornedo-Ortega, Ana M. Espinosa-Oliva#br#   

  1. Departamento de Nutrición y Bromatología, Toxicología y Medicina Legal, Facultad de Farmacia, Universidad de Sevilla, Seville, Spain 
    (Hornedo-Ortega R)
    Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain; and Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla, Sevilla, Spain (Espinosa-Oliva AM)
  • Online:2024-07-15 Published:2023-11-28
  • Contact: Ana M. Espinosa-Oliva, PhD, anaespinosa@us.es.
  • Supported by:
    Authors are also grateful to RHO’s postdoctoral contract (Ayuda IJC2020-045695-I financed by MCIN/AEI/10.13039/501100011033, European Union NextGeneration EU/PRTR).

PDF

105

Abstract: Parkinson’s disease: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, after Alzheimer’s disease, affecting 1% of the general population over the age of 65 years. According to data from the World Health Organization (WHO), its prevalence has doubled in the past 25 years. In 2019, global estimates indicated over 8.5 million individuals with PD and it is suggested that PD caused 329000 deaths, an increase of over 100% since 2000 (WHO, 2022). Although there are pharmacological interventions that improve the quality of life of PD patients, this brain disorder still has no cure.